| CO F-015 |
| Enhanced corneal wound healing after severe injury through once daily application of stem cell secreted factors delivered within a viscoelastic gel carrier |
| 1 Department of Ophthalmology, College of Medicine, The Catholic University
2 Gachon University, Department of Chemical and Biological Engineering
3 Byers Eye Institute at Stanford University School of Medicine |
| Kyung-Sun Na(1),Hyun Jong Lee(2), Hyun Seung Kim(1), David Myung (3) |
|
목적 : Severe corneal injuries such as chemical burns often result in permanent vision loss and remain a clinical challenge. Human mesenchymal stem/stromal cells (hMSCs) and their secreted factors (secretome) have been studied for their anti-scarring, anti-inflammatory and anti-angiogeneic properties, with encouraging results. Here we aimed to deliver lyophilized secretome within a viscoelastic gel composed of hyaluronic acid (HA) and chondroitin sulfate (CS) as a way to enhance corneal re-epithelialization and reduce complications after mechanical and chemical injuries of the cornea.
방법 : Lypholized secretome was added to either diluted HA/CS, plain medium or PBS. Primary rabbit corneal epithelial cells were used to anlyze the effect of secretome and HA/CA regarding in vitro proliferation of cells. Female Sprague-Dawley rats were used either with mechanical debridement model or alkali burn model to test the effect of secretome and HA/CS in vivo.
결과 : Secretome delivered in HA/CS gel reduced scar formation, neovascularization, and hemorrhage after alkaline corneal burns. Treatment of both corneas in vivo and primary corneal epithelial cells in culture with secretome-HA/CS increased expression of CD44 receptors and induced the binding of HA with CD44. Following treatment of chemically-injured eyes, expression of alpha smooth-muscle actin and CD31 were reduced, while expression of ALDH3A1 was maintained relative to uninjured, untreated eyes.
결론 : The results from this study demonstrate the possibility of a highly reproducible and efficient approach to delivering the therapeutic benefits of hMSCs in an acellular, once-daily therapy for severe corneal injury.
|
| |